Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444964 · ClinicalTrials.gov registry record · Phase 3
Growth Hormone Use in Adults With Prader-Willi Syndrome
A Phase 3 study of Prader-Willi Syndrome, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00444964: Completed Phase 3 study of Prader-Willi Syndrome, sponsored by Children's Mercy Hospital Kansas City.
NCT00444964 is a Phase 3 study of Prader-Willi Syndrome that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 11 participants, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00444964, a Phase 3 study of Prader-Willi Syndrome, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.
Primary Outcome
Anthropometric Measures and Body Composition
Conditions Studied
Interventions
- DRUG Nutropin AQ
Study Locations (1)
Missouri
- The Children's Mercy Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-04 |
| Est. Completion | 2012-01-01 |
| Phase | Phase 3 |
What the finished NCT00444964 record still lists
NCT00444964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Nutropin AQ is the first listed.
NCT00444964 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00444964 about?
NCT00444964 is a clinical study titled "Growth Hormone Use in Adults With Prader-Willi Syndrome". The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.
What is the current status of trial NCT00444964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2005-04. Estimated completion is 2012-01-01.
What conditions does trial NCT00444964 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome.
What interventions are being tested in trial NCT00444964?
The interventions under investigation include: Nutropin AQ (DRUG).
Who is sponsoring clinical trial NCT00444964?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00444964 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00444964's enrollment target sits among peer trials
11 16th of 16 higher than 1 of 16 other Prader-Willi Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prader-Willi Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
-
A Study of Pitolisant in Patients With Prader-Willi Syndrome
RECRUITING · Phase 3
-
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
RECRUITING · Phase 1
-
Cerebellar TMS and Satiety in Prader-Willi Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia